Prediction Market Betting on Drug Trials and Approvals Sparks Concern About Undermining Research
Rebecca Robbins / nytimes - Prediction markets on Kalshi and Polymarket now let people wager money on drug approvals. Kalshi also plans to allow bets on clinical trial results.
AI Summary: Betting platforms have started offering markets on clinical trial outcomes and FDA decisions, stirring alarms among regulators and researchers. Critics warn these markets could incentivize insider trading, leak-sensitive information, or distort trial conduct, prompting calls for oversight and clearer rules to protect scientific integrity and participant safety — because apparently Wall Street needed another hobby.
Related Stories
FDA backs three psychedelic studies with special commissioner vouchers / 3 months
Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 3 months
US gray‑market peptides face scrutiny as FDA panel debate looms / 24 days
The peptide problem: Hype outruns evidence, researchers caution / 2 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 2 months
FDA escalates push to withdraw Amgen’s Tavneos; Amgen updates label / 2 months
Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Healthcare Finance, Drug Pricing, Research Funding, Mergers and Acquisitions and look for the RSS link.
StackHealth Time Machine